featured
Lenvatinib Plus Pembrolizumab for Unresectable HCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
J. Clin. Oncol 2020 Jul 27;[EPub Ahead of Print], RS Finn, M Ikeda, AX Zhu, MW Sung, AD Baron, M Kudo, T Okusaka, M Kobayashi, H Kumada, S Kaneko, M Pracht, K Mamontov, T Meyer, T Kubota, CE Dutcus, K Saito, AB Siegel, L Dubrovsky, K Mody, JM LlovetFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.